These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 18813198)
1. Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network. Cartwright T; Richards DA; Boehm KA Cancer Control; 2008 Oct; 15(4):308-13. PubMed ID: 18813198 [TBL] [Abstract][Full Text] [Related]
2. New directions in the management of advanced pancreatic cancer: a review. Rocha-Lima CM Anticancer Drugs; 2008 Jun; 19(5):435-46. PubMed ID: 18418211 [TBL] [Abstract][Full Text] [Related]
3. Recent updates on the role of chemotherapy in pancreatic cancer. Burris HA Semin Oncol; 2005 Aug; 32(4 Suppl 6):S1-3. PubMed ID: 16143160 [TBL] [Abstract][Full Text] [Related]
4. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study. Watkins DJ; Starling N; Cunningham D; Thomas J; Webb J; Brown G; Barbachano Y; Oates J; Chau I Eur J Cancer; 2014 May; 50(8):1422-9. PubMed ID: 24613126 [TBL] [Abstract][Full Text] [Related]
8. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer. Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399 [TBL] [Abstract][Full Text] [Related]
9. Treatment of advanced pancreatic cancer. Ducreux M; Boige V; Malka D Semin Oncol; 2007 Apr; 34(2 Suppl 1):S25-30. PubMed ID: 17449349 [TBL] [Abstract][Full Text] [Related]
10. Systemic therapy for pancreatic cancer. Ko AH; Tempero MA Semin Radiat Oncol; 2005 Oct; 15(4):245-53. PubMed ID: 16183478 [TBL] [Abstract][Full Text] [Related]
11. Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. Li J; Saif MW JOP; 2009 Jul; 10(4):361-5. PubMed ID: 19581735 [TBL] [Abstract][Full Text] [Related]
12. Erlotinib or capecitabine with gemcitabine in pancreatic cancer? de Jager J; Stebbing J Future Oncol; 2006 Apr; 2(2):161-3. PubMed ID: 16563084 [No Abstract] [Full Text] [Related]
13. First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. Oberstein PE; Saif MW JOP; 2011 Mar; 12(2):96-100. PubMed ID: 21386629 [TBL] [Abstract][Full Text] [Related]
14. Metastatic pancreatic cancer response to treatment with cetuximab and gemcitabine plus capecitabine: a case report and review of the literature. Li M; Jiang M; Yan X; Wang F; Luo F Tumori; 2010; 96(5):764-7. PubMed ID: 21302625 [TBL] [Abstract][Full Text] [Related]
15. Improving treatment of pancreatic cancer. Philip PA Lancet Oncol; 2008 Jan; 9(1):7-8. PubMed ID: 18177814 [No Abstract] [Full Text] [Related]
16. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Ko AH; Venook AP; Bergsland EK; Kelley RK; Korn WM; Dito E; Schillinger B; Scott J; Hwang J; Tempero MA Cancer Chemother Pharmacol; 2010 Nov; 66(6):1051-7. PubMed ID: 20130876 [TBL] [Abstract][Full Text] [Related]